Krystal Biotech, Inc. (KRYS) vs Vaxcyte, Inc. (PCVX)
A side-by-side comparison of Krystal Biotech, Inc. and Vaxcyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KRYS
Krystal Biotech, Inc.
$326.81HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PCVX
Vaxcyte, Inc.
$66.70HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — KRYS vs PCVX
growth of $100 · dividends reinvested · last 6yKRYS +600.8% (+38.3%/yr)PCVX +182.3% (+18.9%/yr)KRYS compounded faster over this window
KRYS PCVX
KRYS vs PCVX: by the numbers
- •KRYS is the larger company ($9.63B vs $9.63B market cap).
- •KRYS is profitable (54.82% net margin) while PCVX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | KRYS | PCVX |
|---|---|---|
| P/E ratio | 40.95 | N/A |
| Forward P/E | 42.96 | N/A |
| P/S ratio | 21.87 | N/A |
| P/B ratio | 7.09 | 3.49 |
| EV / EBITDA | 45.09 | N/A |
| FCF yield | 2.68% | N/A |
Profitability
| Metric | KRYS | PCVX |
|---|---|---|
| Gross margin | 93.34% | 0.00% |
| Operating margin | 44.93% | 0.00% |
| Net margin | 54.82% | 0.00% |
| ROE | 17.77% | -38.59% |
| ROIC | 14.41% | -40.65% |
Growth (annualized)
| Metric | KRYS | PCVX |
|---|---|---|
| Total return CAGR (5Y) | 44.28% | 25.08% |
Frequently asked
- Is KRYS or PCVX more profitable?
- KRYS runs the higher net margin — KRYS at 54.82% versus PCVX at 0.00%.
- How have KRYS and PCVX total returns compared?
- Over the past 5 years, KRYS delivered 44.28% and PCVX delivered 25.08% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Krystal Biotech P/E ratioKrystal Biotech ROEVaxcyte ROEKrystal Biotech operating marginVaxcyte operating marginKrystal Biotech revenue growthVaxcyte revenue growthKrystal Biotech free cash flowVaxcyte free cash flow
Krystal Biotech & Vaxcyte appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.